Core Technology Platforms
The following technologies are cornerstones of CureVac's intellectual
property:
- RNActive® for the design of modified mRNA serving a broad range of therapeutic applications,
-
RNAdjuvant® for the use of RNA as an immune stimulant in different kinds of vaccines,
-
PUREmessenger® for the cGMP-production of full-length mRNA.
The combination of these technology platforms enables the Company to develop and manufacture RNA molecules suitable for a broad range of therapeutic applications.